Finished
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
NCT03733210 · Andrei Iagaru · Updated 19 May 2023
- What is being tested
- Panitumumab-IRDye800; 89-Zirconium (Zr-89) Panitumumab; Pinpoint IR IR9000 fluorescence imaging system (FIS); SPY-PHI IR9000 fluorescence imaging system (FIS); Explorer Air camera; PDE-NEO II camera; FIS-00 fluorescence imaging system (FIS); Da Vinci Firefly Imaging System; IGP-ELVIS-v4 Macroscopic Specimen Imager; Vevo 3100 LAZR-X; Pearl Triology Imaging System; Odyssey CLx Imaging System; Leica fluorescence microscope
- For
- Squamous Cell Carcinoma of the Head and Neck; Carcinoma of the Head and Neck
- Kind of study
- Tests a treatment or device on volunteers. Phase 1.
- Who can join
- Ages 19 years and older. About 14 people. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started 7 Jan 2019, ends 9 Aug 2021. Registered 7 Nov 2018.
- Results
- Posted on the registry on 19 May 2023.
In the researchers' words
This study evaluates how well panitumumab-IRDye800 and 89Zr-panitumumab work in identifying cancer that has spread to the lymph nodes in patients with squamous cell head and neck cancer. Panitumumab-IRDye800 is a drug that contains a dye molecule that fluoresces during surgery to indicate cancerous tissue. 89Zr-panitumumab is a drug that contains a small amount of radiation, which makes it visible in positron emission tomography (PET) scans. PET scans make detailed, computerized pictures of areas inside the body where the drug is used. Giving panitumumab-IRDye800 and 89Zr-panitumumab to patients with head and neck cancer may help doctors find metastatic lymph nodes better than current methods \[positron emission tomography (PET); computed tomography (CT); magnetic imaging resonance (MRI), or combinations\].
Sites
- Stanford Cancer Institute Palo AltoPalo Alto, California, United States